Lamivudine plasma levels in chronic hepatitis B patients
Lamivudine has recently been registered for the treatment of chronic hepatitis B patients. The main therapeutic outcome in the studies on which the registration was based was a drop of HBV DNA below 10(7) genome equivalents/ml, the level of detection of the insensitive Abbott Genostics assay. However, as we have reported previously, with the use of sensitive PCR-based assays, individual differences in virological response to lamivudine can be detected. As a first step in analysing the chain of events after oral intake of lamivudine we modified and validated a high-pressure liquid chromatography (HPLC) method to evaluate lamivudine plasma levels. Lamivudine levels in chronic hepatitis B patients who participated in a study on the efficacy of lamivudine were comparable to our reference curve, which was derived from eight chronic hepatitis B patients. From the reference curve, a mean area under the curve (AUC) of 4994 mcg/l.h (SD 1524), a mean t(max) of 42 minutes (SD 11), and a mean C(max) of 1.9 mg/l (SD 0.70) were calculated. Lamivudine exerts its action as the active triphosphate inside the hepatocyte after extensive handling. Therefore, additional steps in the pharmacokinetic process should be evaluated to explore the potential mechanisms that are responsible for the diversity in quantitative HBV DNA response to lamivudine.
|Keywords||Adolescent, Adult, Chromatography, High Pressure Liquid, Female, Hepatitis B, Chronic/*blood/*drug therapy, Humans, Lamivudine/*blood/pharmacokinetics/*therapeutic use, Male, Middle aged, Reverse Transcriptase Inhibitors/*blood/pharmacokinetics/*therapeutic use|
Wolters, L.M.M., Geerlings, C.J., van Dijk, L.J., Niesters, H.G.M., Vulto, A.G., & de Man, R.A.. (2003). Lamivudine plasma levels in chronic hepatitis B patients. Netherlands Journal of Medicine. Retrieved from http://hdl.handle.net/1765/10123